Discover 5 insights about psoriatic arthritis from rheumatology experts, including pain management strategies, treatment ...

A rheumatologist discusses how her understanding of chronic pain in PsA has evolved—and how it affects her approach to ...

Visible signs of psoriatic arthritis appear months and even years before a person develops the full-blown inflammatory joint ...

The following is a summary of “Association Between Patient Perception of Disease Status and Different Components of the ...

Having psoriasis raises your risk of psoriatic arthritis — and rheumatoid arthritis, too. Make sure you can tell these two forms of arthritis apart.

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

Discover the early warning signs of psoriatic arthritis that could prevent permanent joint damage, plus expert advice on treatment options and daily management.

The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints ...

Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.